Christopher T Rentsch, PhD, FISPE
Assistant Professor AdjunctCards
About
Research
Publications
2025
Glucagon-like peptide-1 receptor agonists but not dipeptidyl peptidase-4 inhibitors reduce alcohol intake
Farokhnia M, Tazare J, Pince C, Bruns N, Gray J, Re V, Fiellin D, Kranzler H, Koob G, Justice A, Vendruscolo L, Rentsch C, Leggio L. Glucagon-like peptide-1 receptor agonists but not dipeptidyl peptidase-4 inhibitors reduce alcohol intake. Journal Of Clinical Investigation 2025 PMID: 40048376, DOI: 10.1172/jci188314.Peer-Reviewed Original ResearchAlcohol use disorderTreat alcohol use disorderGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsPeptidase-4 inhibitorsDPP-4isOperant oral alcohol self-administrationDPP-4iAlcohol intakeOral alcohol self-administrationBinge-like alcohol drinkingBaseline alcohol use disordersReceptor agonistsAlcohol self-administrationAlcohol-dependent ratsReduce alcohol drinkingAlcohol drinkingGLP-1RAAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) scoresReduce alcohol intakeGLP-1RAsImpact of dipeptidyl peptidase-4 inhibitorReverse translational approachBaseline hazardous drinkingTime to direct-acting antivirals initiation and liver-related events in people with HIV and Hepatitis C virus.
Chalouni M, Van Santen D, Berenguer J, Jarrin I, Miro J, Klein M, Young J, Torgersen J, Rentsch C, Gill M, Epstein R, Linas B, Zangerle R, Surial B, Rauch A, Touloumi G, Papadopoulos A, Wittkop L, Van Der Valk M, Boyd A, Monforte A, Puoti M, Logan R, Rein S, Hernán M, Lodi S. Time to direct-acting antivirals initiation and liver-related events in people with HIV and Hepatitis C virus. AIDS 2025 PMID: 39970192, DOI: 10.1097/qad.0000000000004161.Peer-Reviewed Original ResearchRisk of liver-related eventsDirect-acting antivirals initiationHIV-HCV co-infectionLiver-related eventsDirect-acting antiviralsHIV virologic suppressionAntiretroviral treatmentVirologic suppressionHIV-HCVCo-infectionHistory of injection drug useInjection drug useHepatitis C virusAntiviral initiationSuppress HIVDAA initiationHCV transmissionC virusEarly initiationCure HCVDelayed initiationHIVRisk differenceClinical practiceDrug useCannabis Use and Self-Reported Bothersome Symptoms in People with HIV
Wrona A, Justice A, Tate J, Rentsch C, Gordon K, Kidwai-Khan F, Silverberg M, Satre D, Marconi V, Ingle S, Sterne J, Cavassini M, Bryant K, McGinnis K. Cannabis Use and Self-Reported Bothersome Symptoms in People with HIV. Cannabis 2025, 8: 177-190. PMID: 39968492, PMCID: PMC11831903, DOI: 10.26828/cannabis/2025/000269.Peer-Reviewed Original ResearchCannabis useKaiser Permanente Northern CaliforniaSwiss HIV Cohort StudyHIV Symptom IndexSelf-reportBothersome symptomsSubstance useAssociations of self-reportedBothersome levelSelf-reported substanceMental health symptomsSymptom IndexSelf-reported informationHIV Cohort StudyPatterns of associationWeight lossPresence/absence of symptomsCross-cohort studyLogistic regression modelsHealth symptomsCannabisHealth outcomesLoss of appetiteHIV cohortStudy HIVUsing Quantitative Bias Analysis to Adjust for Misclassification of COVID‐19 Outcomes: An Applied Example of Inhaled Corticosteroids and COVID‐19 Outcomes
Bokern M, Rentsch C, Quint J, Hunnicutt J, Douglas I, Schultze A. Using Quantitative Bias Analysis to Adjust for Misclassification of COVID‐19 Outcomes: An Applied Example of Inhaled Corticosteroids and COVID‐19 Outcomes. Pharmacoepidemiology And Drug Safety 2025, 34: e70086. PMID: 39776023, PMCID: PMC11706700, DOI: 10.1002/pds.70086.Peer-Reviewed Original ResearchConceptsProbabilistic bias analysisRisk of COVID-19 hospitalisationCOVID-19 hospitalisationChronic obstructive pulmonary diseaseOutcome misclassificationInhaled corticosteroid usersCOVID-19 outcomesIncreased risk of COVID-19 hospitalisationClinical Practice Research Datalink AurumInhaled corticosteroidsLogistic regressionQuantitative bias analysisBias analysisTriple therapySummary-levelObstructive pulmonary diseaseImpact treatment effect estimatesBenzodiazepine and z-drug prescribing in critical care survivors and the risk of rehospitalisation or death due to falls/trauma and due to any cause: a retrospective matched cohort study using the UK Clinical Practice Research Datalink
Mansi E, Rentsch C, Bourne R, Jeffery A, Guthrie B, Lone N. Benzodiazepine and z-drug prescribing in critical care survivors and the risk of rehospitalisation or death due to falls/trauma and due to any cause: a retrospective matched cohort study using the UK Clinical Practice Research Datalink. Intensive Care Medicine 2025, 51: 125-136. PMID: 39774867, DOI: 10.1007/s00134-024-07762-4.Peer-Reviewed Original ResearchMeSH KeywordsAccidental FallsAcetamidesAdultAgedAged, 80 and overAzabicyclo CompoundsBenzodiazepinesCohort StudiesCritical CareFemaleHumansHypnotics and SedativesMaleMiddle AgedPatient ReadmissionPiperazinesProportional Hazards ModelsPyrimidinesRetrospective StudiesSurvivorsUnited KingdomWounds and InjuriesConceptsCritical care survivorsUK Clinical Practice Research DatalinkClinical Practice Research DatalinkZ-drug prescribingAssociated with increased riskPalliative careZ-drugsAssociated with increased risk of all-causeRisk of all-causeCohort studyConfidence intervalsBenzodiazepines/Z-drugsMental health problemsRisk of rehospitalisationMatched cohort studyVulnerable patient groupRetrospective matched cohort studyTreatment naive individualsAll-causeMethodsRetrospective cohort studyHazard ratioHealth problemsPrescribed benzodiazepinesPrescribingHighest prevalenceUtility of Candidate Genes From an Algorithm Designed to Predict Genetic Risk for Opioid Use Disorder
Davis C, Jinwala Z, Hatoum A, Toikumo S, Agrawal A, Rentsch C, Edenberg H, Baurley J, Hartwell E, Crist R, Gray J, Justice A, Gelernter J, Kember R, Kranzler H, Muralidhar S, Moser J, Deen J, Tsao P, Gaziano J, Hauser E, Kilbourne A, Matheny M, Oslin D, Churby L, Whitbourne S, Brewer J, Shayan S, Selva L, Pyarajan S, Cho K, DuVall S, Brophy M, Stephens B, Connor T, Argyres D, Assimes T, Hung A, Kranzler H, Aguayo S, Ahuja S, Alexander K, Androulakis X, Balasubramanian P, Ballas Z, Beckham J, Bhushan S, Boyko E, Cohen D, Dellitalia L, Faulk L, Fayad J, Fujii D, Gappy S, Gesek F, Greco J, Godschalk M, Gress T, Gupta S, Gutierrez S, Harley J, Hamner M, Hurley R, Iruvanti P, Jacono F, Jhala D, Kinlay S, Landry M, Liang P, Liangpunsakul S, Lichy J, Mahan C, Marrache R, Mastorides S, Mattocks K, Meyer P, Moorman J, Morgan T, Murdoch M, Norton J, Okusaga O, Oursler K, Poon S, Rauchman M, Servatius R, Sharma S, Smith R, Sriram P, Strollo P, Tandon N, Villareal G, Walsh J, Wells J, Whittle J, Whooley M, Wilson P, Xu J, Yeh S, Bast E, Dryden G, Hogan D, Joshi S, Lo T, Morales P, Naik E, Ong M, Petrakis I, Rai A, Yen A. Utility of Candidate Genes From an Algorithm Designed to Predict Genetic Risk for Opioid Use Disorder. JAMA Network Open 2025, 8: e2453913. PMID: 39786773, PMCID: PMC11718552, DOI: 10.1001/jamanetworkopen.2024.53913.Peer-Reviewed Original ResearchConceptsOpioid use disorder riskElectronic health record dataHealth record dataInternational Classification of DiseasesOpioid use disorderClassification of DiseasesGenetic variantsInternational ClassificationGenetic riskRecord dataRisk of opioid use disorderMillion Veteran ProgramOpioid use disorder diagnosisUse disorderCase-control studyVeteran ProgramMain OutcomesDiagnostic codesClinical careOpioid exposurePharmacy recordsLogistic regressionRisk allelesNagelkerke R2Clinically useful modelHow Should Meaningful Evidence Be Generated From Datasets?
Morton C, Rentsch C. How Should Meaningful Evidence Be Generated From Datasets? The AMA Journal Of Ethic 2025, 27: e27-33. PMID: 39745911, DOI: 10.1001/amajethics.2025.27.Peer-Reviewed Original ResearchWhat Are High-Quality Race and Ethnicity Data and How Are They Used in Health Equity Research?
Rentsch C, Siddiqui M, Mathur R. What Are High-Quality Race and Ethnicity Data and How Are They Used in Health Equity Research? The AMA Journal Of Ethic 2025, 27: e34-43. PMID: 39745912, DOI: 10.1001/amajethics.2025.34.Peer-Reviewed Original Research
2024
Four targets: an enhanced framework for guiding causal inference from observational data
Lu H, Li F, Lesko C, Fink D, Rudolph K, Harhay M, Rentsch C, Fiellin D, Gonsalves G. Four targets: an enhanced framework for guiding causal inference from observational data. International Journal Of Epidemiology 2024, 54: dyaf003. PMID: 39868475, PMCID: PMC11769716, DOI: 10.1093/ije/dyaf003.Peer-Reviewed Original ResearchStudy protocol: Comparison of different risk prediction modelling approaches for COVID-19 related death using the OpenSAFELY platform
Collaborative T, Williamson E, Tazare J, Bhaskaran K, Walker A, McDonald H, Tomlinson L, Bacon S, Bates C, Curtis H, Forbes H, Minassian C, Morton C, Nightingale E, Mehrkar A, Evans D, Nicholson B, Leon D, Inglesby P, MacKenna B, Cockburn J, Davies N, Hulme W, Morley J, Douglas I, Rentsch C, Mathur R, Wong A, Schultze A, Croker R, Parry J, Hester F, Harper S, Perera R, Grieve R, Harrison D, Steyerberg E, Eggo R, Diaz-Ordaz K, Keogh R, Evans S, Smeeth L, Goldacre B. Study protocol: Comparison of different risk prediction modelling approaches for COVID-19 related death using the OpenSAFELY platform. Wellcome Open Research 2024, 5: 243. PMID: 39931522, PMCID: PMC11809169, DOI: 10.12688/wellcomeopenres.16353.2.Peer-Reviewed Original ResearchRisk prediction modelPrimary care electronic health records dataElectronic health record dataTime-varying measuresHealth record dataRisk of poor outcomesOpenSAFELY platformChronic disease settingsRestricted social contactDeath dataCOVID-19 related deathsWorld Health OrganizationCohort approachCOVID-19 deathsRecord dataCOVID-19Population of adult patientsHealth OrganizationRisk predictionOpenSAFELYSocial contactPerceived riskPolicy changesRelated deathsAdult patients
Academic Achievements & Community Involvement
News & Links
News
- January 02, 2025
Yale Department of Internal Medicine Faculty Promotions and Appointments (January 2025)
- March 11, 2024
Excess Deaths During the COVID-19 Pandemic
- February 02, 2023Source: NIH National Institute on Drug Abuse Intramural Research Program
Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies
- August 11, 2021
Congratulations to New Department Faculty! (August 2021)